FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer Pursuant to Rule 13a - 16 under the Securities Exchange Act of 1934

For the month of May 2008

ICON plc (Registrant's name)

0-29714 (Commission file number)

· · · · · · · · · · · · · · · · · · ·	Business Park, Leo Idress of principal	-	vn, Dublin 18, Ireland. ve offices)
Indicate by check mark whether the registrant files or will file	annual reports und	ler cover	Form 20-F or Form 40-F.
Yes	X	No	
Indicate by check mark whether the registrant is submitting the	Form 6-K in pap	er as per	nitted by Regulation S-T Rule 101(b)(1):
Yes		No	X
Indicate by check mark whether the registrant is submitting the	Form 6-K in pape	er as per	nitted by Regulation S-T Rule 101(b)(7):
Yes		No	X
Indicate by check mark whether the registrant by furnishing Commission pursuant to Rule 12g3-2(b) under the Securities E	_		ed in this Form is also thereby furnishing the information to the
Yes		No	X
If "Yes" is marked, indicate below the file number assigned to	the registrant in co	onnectio	ı with Rule 12g3-2(b):82 N/A

Other Events.

The registrant hereby incorporates by reference the press release attached hereto as Exhibit 99.1 into this report.

EXHIBIT INDEX

Exhibit

99.1

Number Description of Exhibit

Press Release - ICON plc announces appointment of Professor Dermot Kelleher to the Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ICON p

May 29, 2008

Date

/s/ Peter Gray

Peter Gray

Chief Executive Officer

ICON plc announces appointment of Professor Dermot Kelleher to the Board of Directors. (NASDAQ:ICLR) (ISIN: IE0001827041)

Dublin, Ireland, May 28 2008 – ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Professor Dermot Kelleher as a non-executive Director.

Professor Kelleher was appointed unanimously by ICON's board of directors and in accordance with the company's Articles of Association will stand for reelection by ICON's shareholders at the Company's next annual general meeting.

Professor Kelleher is currently Head of the School of Medicine at Trinity College, Dublin, Ireland and Director of the Institute of Molecular Medicine in Dublin. His research interests are broad ranging in the fields of Gastroenterology, Immunology and Molecular Biology and over a distinguished thirty year career he has led significant research projects in this field. Alongside his notable academic appointments he has served as a visiting research scientist with Lilly Research laboratories and has been a founder of a number of biotechnology companies.

"We are delighted to welcome Professor Dermot Kelleher to the Board of ICON", commented Chairman Dr John Climax. "With his extensive experience in clinical research and in particular his academic insight into novel medicines, he will prove an invaluable addition to the Board."

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has approximately 6,150 employees, operating from 69 locations in 36 countries. Further information is available at www.iconplc.com.

Source: ICON plc

Contact: Investor Relations 1-888-381-7923 or Ciaran Murray CFO + 353 –1-291-2000 Both at ICON.